Literature DB >> 16105103

Anti-phospholipid antibodies against phosphatidylinositol, and phosphatidylserine are more significant in reproductive failure than antibodies against cardiolipin only.

Zdenka Ulcova-Gallova1, Vladimir Krauz, Pavla Novakova, Lucie Milichovska, Zdenka Micanova, Katerina Bibkova, Renata Sucha, Jiri Turek, Miroslav Balvin, Zdenek Rokyta.   

Abstract

PROBLEM: The humoral immune response to phospholipids was investigated in women with reproductive failure [1073 women after one in vitro fertilization (IVF), 853 women after two and more IVF, 627 women after three and more repeated spontaneous miscarriages or missed abortions, 412 women after diagnostic laparoscopy] and compared with that of 391 healthy fertile women. METHOD OF STUDY: Sera from all women in the study were tested by enzyme-linked immunosorbent assay (ELISA) for the detection of IgG, IgA, and IgM isotypes of antibodies against seven phospholipids (aPLs), i.e. cardiolipin, L-phosphatidylserine, phosphatidylglycerol, phosphatidylinositol, phosphatidylethanolamine, phosphatidylacid as well as against beta2-glycoprotein I.
RESULTS: Patients after two and more IVF (48 and 50%, respectively), patients with three and more repeated spontaneous miscarriages (50 and 46.5%, respectively) are associated with significantly higher serum levels of aPLs against inositol, and L-serine (P < 0.01). A quarter of them were positive for three and more aPLs.
CONCLUSION: It seems that determination of aPLs only against cardiolipin in reproductive failure is not sufficient for obstetric-gynecology diagnosis as the primary anti-phospholipid syndrome. Our long-ranging study (from 1998 to 2003) shows the necessity to test for a complete aPLs profile. Sera from patients after two and more IVF procedures, and sera from women after three and more repeated abortions are immunologically more active than sera from women after one unsuccessful IVF and sera from women after diagnostic laparoscopy. This important result is very significant for future treatment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16105103     DOI: 10.1111/j.1600-0897.2005.00294.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  6 in total

Review 1.  Antiphospholipid antibody-mediated reproductive failure in antiphospholipid syndrome.

Authors:  Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

Review 2.  The role of antiphospholipid antibodies (aPls) in infertile women: the long-lasting experience.

Authors:  Zdenka Ulcova-Gallova
Journal:  Reprod Med Biol       Date:  2014-10-07

3.  Possible Effect of Extended Use of Hormonal Contraception on Increased Levels of Antiphospholipid Antibodies in Infertile Women.

Authors:  Z Ulcova-Gallova; K Bibkova; Z Micanova; P Losan; K Babcova
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-03       Impact factor: 2.915

4.  Performance Evaluation and Clinical Associations of Immunoassays That Detect Antibodies to Negatively Charged Phospholipids Other Than Cardiolipin.

Authors:  Amaris Castanon; Grant Pierre; Rohan Willis; E Nigel Harris; Elizabeth Papalardo; Zurina Romay-Penabad; Alvaro Schleh; Praveen Jajoria; Monica Smikle; Karel DeCeulaer; Anne Tebo; Troy Jaskowski; Marta M Guerra; D Ware Branch; Jane E Salmon; Michelle Petri; Emilio B Gonzalez
Journal:  Am J Clin Pathol       Date:  2018-03-29       Impact factor: 2.493

5.  Anti-Phosphatidylserine/Prothrombin Antibodies Are Associated with Adverse Pregnancy Outcomes.

Authors:  Polona Žigon; Katja Perdan Pirkmajer; Matija Tomšič; Tanja Kveder; Borut Božič; Snežna Sodin Šemrl; Saša Čučnik; Aleš Ambrožič
Journal:  J Immunol Res       Date:  2015-05-20       Impact factor: 4.818

6.  Presence of antiphospholipid antibodies is associated with increased implantation failure following in vitro fertilization technique and embryo transfer: A systematic review and meta-analysis.

Authors:  Eirini Papadimitriou; Georgios Boutzios; Alexander G Mathioudakis; Nikos F Vlahos; Panayiotis Vlachoyiannopoulos; George Mastorakos
Journal:  PLoS One       Date:  2022-07-27       Impact factor: 3.752

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.